Payers, gastroenterologists share excitement over JAK inhibitors — 5 key notes


Payers and gastroenterologists expressed shared excitement for the potential Janus kinase inhibitors have in treating inflammatory bowel disease, according to a survey by Decision Resources Group.

Here's what you should know:

1. The excitement is directed at Pfizer's Xeljanz and Gilead/Galapagos' filgotinib. Payers and physicians believe the drugs will have a sizable impact on ulcerative colitis and Crohn's disease.

2. Surveyed gastroenterologists believe they'll start prescribing the drugs within the first year they become available on the market.

3. Survey respondents indicated Remicade has "favorable market access" despite the launch of a biosimilar.

4. Physicians believe payers will push for the adaptation of the biosimilar over time.

5. Physicians and payers believe TNF-inhibitors will be the standard first-line biologic of choice for IBD, in the face of emerging novel biologic and oral therapies.

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers